<DOC>
	<DOCNO>NCT02493777</DOCNO>
	<brief_summary>This Phase 3 pivotal efficacy trial examine effect HLD200 ( methylphenidate ) patient age 6-12 year ADHD laboratory classroom set . This study 6-week open-label treatment optimization period follow one week randomize , double-blind , placebo-controlled test phase .</brief_summary>
	<brief_title>A Pivotal Efficacy Trial Evaluate HLD200 Children With ADHD Classroom Setting</brief_title>
	<detailed_description />
	<mesh_term>Attention Deficit Disorder Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<criteria>1 . Subjects must male female child ( 6 12 year time consent ) . 2 . Subjects must diagnosis ADHD define DSM5 criterion confirmation use Mini International Neuropsychiatric Interview Children Adolescents ( MINIKID ) . 3 . Subjects must Baseline ADHDRSIV score 90th percentile normalize sex age least 1 follow category : 1 ) Hyperactive Impulse ; 2 ) Inattentive ; 3 ) Total Score . In addition , ADHDRSIV Total Score must great equal 26 . 4 . Subjects must Clinical Global Impression Severity ( CGIS ) score great equal 4 CGIP score &gt; 10 Baseline Visit . 5 . Subjects currently MPH treatment must either 1 ) prior experience MPH treatment show clinical response therapy time ; 2 ) treat dose MPH show clinical response acceptable tolerability MPH â‰¥2 week prior screen . 6 . Parental legal guardian confirmation beforeschool function impairment difficulty perform morning routine . 7 . Regular weekday morning routine le 30 minute . 8 . Subject must consider clinically appropriate treatment MPH HLD200 , include ability swallow treatment capsule . 9 . Subject must general good health base upon medical history , physical examination , laboratory result ( include urine drug screen ) . 10 . Subject parent legal guardian must able read , write , and/or understand level sufficient provide inform consent ( parent/legal guardian ) assent ( subject ) prior study participation complete studyrelated material . Subject parent/legal guardian must plan available entire study period . 11 . Female subject childbearing potential ( i.e. , postmenarche ) require negative result urine pregnancy test screening ( give specific instruction avoid pregnancy study ) . 12 . A medically highly effective form birth control must use study 90 day thereafter subject either sex childbearing potential . Examples medically highly effective form birth control follow : No sexual activity Use acceptable method birth control include intrauterine device , oral , implantable , injectable contraceptive . 1 . History , current , medical condition laboratory result , opinion investigator , unfavorably alters riskbenefit study participation , may jeopardize subject safety , may interfere satisfactory completion study studyrelated procedure . 2 . Serious structural cardiac abnormality , cardiomyopathy , serious heart rhythm abnormality , cardiac problem may place subject increase vulnerability sympathomimetic effect stimulant drug . 3 . History seizure disorder ( except febrile seizure prior age 5 least 1 year prior study participation ) , Tourette 's disorder , intellectual disability minor severity great ( DSM5 criterion ) . 4 . History psychosis , bipolar disorder , anorexia nervosa , bulimia , suicide attempt . Current depression , anxiety , conduct/behavior disorder , substance use disorder , psychiatric condition , investigator 's opinion , may jeopardize subject safety may interfere satisfactory completion study studyrelated procedure . 5 . Active suicidal ideation evidence ideation score 2 great CSSRS . 6 . History severe allergic reaction MPH . 7 . History response intolerance adverse effect MPH ; 8 . Alanine aminotransferase ( ALT ) , aspartate aminotransferase ( AST ) , total bilirubin , creatinine great 1.5x upper limit normal . Elevated bilirubin due Gilbert 's syndrome exclusionary . 9 . History alcohol abuse illicit drug use . 10 . Use prescription medication ( except allow medication ; see Section 8.1.2 ) within 7 day Baseline ( Visit 2 ) , except ADHD stimulant medication ( 5 day ) monoamine oxidase inhibitor ( MAOIs ) ( 14 day ) , overthecounter medication ( except birth control allow medication ) within 3 day precede Baseline ( Visit 2 ) . Medications cover allowed medication prohibit medication ( Section 8.1.1 ) must clear medical monitor prior enrolling subject . 11 . Participation clinical study investigational drug within 30 day precede study enrollment . 12 . Previous treatment experience HLD200 . 13 . Positive screen illicit drug use nicotine and/or current health condition use medication might confound result study increase risk subject . 14 . In opinion investigator , subject may problem comply protocol procedure protocol , could face unnecessary safety risk study . This include current health condition use medication might confound result study increase risk subject . 15 . Subject 's systolic diastolic blood pressure measurement exceed 95th percentile age , sex , height Baseline visit . 16 . Subject significantly underweight base Centers Disease Control Prevention body mass index ( BMI ) forage sexspecific value Screening Visit . Significantly underweight define BMI &lt; 5th percentile . 17 . Subject significantly overweight base Centers Disease Control Prevention BMIforage sex specific value Screening Visit . Significantly overweight define BMI &gt; 95th percentile .</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>12 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>